{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:17:11Z","timestamp":1781932631774,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017499","name":"Dane O. Kildsig Center for Pharmaceutical Processing Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017499","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xphs.2025.103960","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:35:21Z","timestamp":1755495321000},"page":"103960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Crystal defects cause nitrosamine formation in ranitidine under accelerated storage conditions"],"prefix":"10.1016","volume":"114","author":[{"given":"Jianchao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas John","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber S.","family":"Jannasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8154-6360","authenticated-orcid":false,"given":"Eric J.","family":"Munson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2025.103960_bib0001","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.joc.0c02774","article-title":"An organic chemist\u2019s guide to N-nitrosamines: their structure, reactivity, and role as contaminants","volume":"86","author":"Beard","year":"2021","journal-title":"J Org Chem"},{"issue":"9","key":"10.1016\/j.xphs.2025.103960_bib0002","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"5","key":"10.1016\/j.xphs.2025.103960_bib0003","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.xphs.2023.01.027","article-title":"N-nitrosamine formation in pharmaceutical solid drug products: experimental observations","volume":"112","author":"Moser","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103960_bib0004","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/acs.oprd.2c00366","article-title":"Formation of dialkyl-N-nitrosamines in aqueous solution: an experimental validation of a conservative predictive model and a comparison of the rates of dialkyl and trialkylamine nitrosation","volume":"27","author":"Ashworth","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"9","key":"10.1016\/j.xphs.2025.103960_bib0005","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","article-title":"Nitrosamine contamination in pharmaceuticals: threat, impact, and control","volume":"110","author":"Tuesuwan","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103960_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105355","article-title":"A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products","author":"Akkaraju","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2025.103960_bib0007","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201csaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2025.103960_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113460","article-title":"Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography\u2013tandem mass spectrometry","volume":"189","author":"Lim","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2025.103960_bib0009","series-title":"Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry","author":"Administration","year":"2021"},{"key":"10.1016\/j.xphs.2025.103960_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113582","article-title":"HS-SPME-GCMS\u2013 as an alternative method for NDMA analysis in ranitidine products","volume":"191","author":"Alshehri","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2025.103960_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.124102","article-title":"Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals","volume":"254","author":"Wichitnithad","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.xphs.2025.103960_bib0012","unstructured":"Przybyla J., Carlson-Lynch H., Roney N., Citra M., Heit C. 2022. Toxicological profile for n-nitrosodimethylamine (NDMA): draft for public comment."},{"issue":"6","key":"10.1016\/j.xphs.2025.103960_bib0013","first-page":"1499","article-title":"Metabolism of N-nitrosodialkylamines by human liver microsomes","volume":"48","author":"Yoo","year":"1988","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.xphs.2025.103960_bib0014","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.3390\/ijerph18189465","article-title":"Estimated cancer risks associated with nitrosamine contamination in commonly used medications","volume":"18","author":"Li","year":"2021","journal-title":"Int J Env Res Public Health"},{"key":"10.1016\/j.xphs.2025.103960_bib0015","article-title":"Updated information | Recommended acceptable intake Limits for nitrosamine drug substance-related impurities (NDSRIs). Ed.: U.S","author":"USFaD","year":"2023","journal-title":"Food Drug Adm"},{"issue":"4","key":"10.1016\/j.xphs.2025.103960_bib0016","article-title":"Case report on intravenous ranitidine induced anaphylactic reaction in cholangiocarcinoma patient","volume":"10","author":"Moudgil","year":"2017","journal-title":"Indian J Pharm Pract"},{"issue":"4","key":"10.1016\/j.xphs.2025.103960_bib0017","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/cts.12995","article-title":"Is this the end for ranitidine? NDMA presence continues to confound","volume":"14","author":"Wagner","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2025.103960_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1376-1","article-title":"Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities","volume":"20","author":"Charoo","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2025.103960_bib0019","series-title":"Laboratory Tests\u2013Ranitidine","year":"2019"},{"issue":"12","key":"10.1016\/j.xphs.2025.103960_bib0020","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.oprd.0c00462","article-title":"Ranitidine\u2014Investigations into the root cause for the presence of N-nitroso-N, N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products","volume":"24","author":"King","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"9","key":"10.1016\/j.xphs.2025.103960_bib0021","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1248\/cpb.c21-00289","article-title":"N-nitrosodimethylamine (NDMA) formation from ranitidine impurities: possible root causes of the presence of NDMA in ranitidine hydrochloride","volume":"69","author":"Yokoo","year":"2021","journal-title":"Chem Pharm Bull"},{"issue":"5","key":"10.1016\/j.xphs.2025.103960_bib0022","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.xphs.2022.11.011","article-title":"Ranitidine: a proposed mechanistic rationale for NDMA formation and a potential control strategy","volume":"112","author":"Harmon","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103960_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124832","article-title":"Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets","volume":"666","author":"Shakleya","year":"2024","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2025.103960_bib0024","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.xphs.2023.06.013","article-title":"Bumetanide as a model NDSRI substrate: n-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets","volume":"112","author":"Shakleya","year":"2023","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2025.103960_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jps.20684","article-title":"Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability","volume":"96","author":"Lubach","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103960_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12249-012-9879-z","article-title":"Investigating gabapentin polymorphism using solid-state NMR spectroscopy","volume":"14","author":"Dempah","year":"2013","journal-title":"Aaps Pharmscitech"},{"issue":"10","key":"10.1016\/j.xphs.2025.103960_bib0027","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/cpb.c20-00431","article-title":"Temperature-dependent formation of N-nitrosodimethylamine during the storage of ranitidine reagent powders and tablets","volume":"68","author":"Abe","year":"2020","journal-title":"Chem Pharm Bull"},{"issue":"1","key":"10.1016\/j.xphs.2025.103960_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.38212\/2224-6614.1133","article-title":"N-nitrosodimethylamine (NDMA) contamination of ranitidine products: a review of recent findings","volume":"29","author":"Aldawsari","year":"2021","journal-title":"J Food Drug Anal"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:29:54Z","timestamp":1766525394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022354925004149"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103960","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crystal defects cause nitrosamine formation in ranitidine under accelerated storage conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103960"}}